The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2024 | Using an AI model to quantify under-utilization of alloSCT for AML in the UK
Thomas Coats, PhD, Royal Devon University Hospital Foundation Trust, Exeter, UK, discusses the use of an artificial intelligence (AI) model to quantify the under-utilization of allogeneic stem cell transplantation (alloSCT) for patients with acute myeloid leukemia (AML) in the United Kingdom. Despite a lack of robust data sets, expert estimations were used, and high-level modeling identified substantial under-utilization of transplantation at first remission in this patient population. This interview took place at the 64th Annual Scientific Meeting of the British Society for Haematology (BSH) Congress in Liverpool, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
